YAP1 upregulation decreased the IC50 of FLT3 inhibitor sorafenib, HHT, and cytarabine Ara-C, confirming that YAP1 activation could resensitize FLT3-ITD+ AML cells (Figure 2E). The gene discussed is YAP1; the disease is acute myeloid leukemia.